Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pemigatinib works in treating patients with colorectal
cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the
body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the
growth of tumor cells by blocking FGFR, which is needed for cell growth.